phrma
-
Lawsuits Against Medicare Drug Negotiations Are Mounting, But They Probably Won’t Be Able to Stop The Plan
Lawsuits filed in opposition to the White House’s drug pricing negotiation program are beginning to mount, but legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle. However, these lawsuits still could delay when the government’s ability to negotiate price goes into effect.
-
AHIP Targets Big Pharma in New Campaign
America’s Health Insurance Plans’ new campaign aims to show how health insurers are working to create savings for Americans while also targeting Big Pharma (or more specifically drug manufacturers) for increasing drug costs. The ads will be distributed on TV, social media and streaming services.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
BioPharma, Pharma, Policy, Social Determinants, SYN
Drug-industry survey blames insurer practices for barriers to care
Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.
-
Medicare drug price negotiation provision could avoid concerns about stifling innovation
Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.
-
New study ties pharma payments to prescription practices
Recent efforts to improve transparency haven’t made much of a difference, one author noted. But earlier reforms made a dent the “most egregious” practices.
-
Federal judge strikes down rule requiring drug prices in TV ads
U.S. District Judge Amit Mehta in Washington, D.C. ruled in favor of pharma companies challenging the rule in court because of what he said was a lack of statutory authority from the HHS to govern drug marketing.
-
Can changing rebate rules stop the ‘carousel’ of insulin pricing hikes?
At an event during the annual American Diabetes Association Scientific Sessions in San Francisco, representatives from PBM, health plan, drug manufacturing and patient advocacy groups came together to discuss the causes of increasing insulin prices and potential solutions to the problem.
-
HHS implements rule to require list prices in television drug ads
The changes will take place 60 days after the rule is published in the Federal Register. Industry trade group PhRMA have opposed the rule, saying it will lead to consumer confusion and sticker shock that could discourage medication use.
-
Scott Gottlieb resigns as FDA commissioner
The Washington Post reported Tuesday that Gottlieb, who was appointed FDA commissioner in May 2017, is leaving the agency. In January, he had denied rumors that he would be departing.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Trump calls Medicare Part B proposal ‘revolutionary,’ but experts see limited benefits
Accusations of “freeloading” seen as misleading, and the proposed changes – which would start in 2020 – wouldn’t help patients covered under Part D or commercial plans.
-
Drug prices in DTC ads invite consumer confusion, but administration can still require them
A legal expert compared mandatory prices in ads to food labeling, but another expert said mandating them risks scaring patients out of taking life-saving medicines.
-
Drugmakers propose pricing information in DTC ads, but Trump administration says it’s not enough
The industry’s main lobbying group, PhRMA, updated its direct-to-consumer ad guidelines to include pricing information, but HHS secretary says voluntary action is insufficient.
-
FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
-
Battleground on drug price legislation shifts to states and so does lobbying by PhRMA
With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures.
-
Facing showdown on high drug prices, industry group PhRMA revenue surges to highest level in 7 years
Pharmaceutical Research and Manufacturers of America’s state and federal lobbying spending rose by more than two-thirds from the previous year, to $57 million.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
